Advertisement
Cardiovascular
Subscribe to Cardiovascular
View Sample

FREE Email Newsletter

MAQUET Cardiovascular Receives FDA 510(k) Clearance and CE Mark for Its New SENSATION PLUSâ„¢ Intra-Aortic Balloon Catheter

September 20, 2011 5:34 am | by Bio-Medicine.Org | News | Comments

MAHWAH, N.J., Sept. 20, 2011 /- MAQUET Cardiovascular, a leading provider of cardiovascular technologies, announced today that it has received both 510(k) clearance from the U.S. Food & Drug Administration (FDA) and CE mark approval from the British Standards Institution (BSi) for its...

Thoratec Presentation at Lazard Capital Markets Circulatory Assist Device Day to be Webcast

September 20, 2011 5:33 am | by Bio-Medicine.Org | News | Comments

PLEASANTON, Calif., Sept. 20, 2011 /- Thoratec Corporation (NASDAQ: THOR ), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, said today it will be participating in the Lazard Capital Markets 3rd Annual Circulatory...

Watson Pharmaceuticals Announces Approval of Amphastar's Generic LOVENOX(R)

September 20, 2011 12:33 am | by Bio-Medicine.Org | News | Comments

PARSIPPANY, N.J., Sept. 19, 2011 /- Watson Pharmaceuticals, Inc. (NYSE: WPI ) today announced that Amphastar Pharmaceuticals, Inc., has received U.S. Food and Drug Administration ("FDA") approval of its Abbreviated New Drug Application (ANDA) for Enoxaparin Sodium Injection in the...

Advertisement

HeartWare to Present at The Lazard Capital Markets 3rd Annual Circulatory Assist Device Day

September 19, 2011 1:33 pm | by Bio-Medicine.Org | News | Comments

FRAMINGHAM, Mass. and SYDNEY, Sept. 19, 2011 /- HeartWare International, Inc. (NASDAQ: HTWR - ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug...

South and Central America Cardiovascular Devices Market Outlook to 2017

September 19, 2011 9:33 am | by Bio-Medicine.Org | News | Comments

NEW YORK, Sept. 19, 2011 /- Reportlinker.com announces that a new market research report is available in its catalogue: South and Central America Cardiovascular Devices Market Outlook to 2017 ...

Studying Fluid Overflow in Patients With Devices

September 19, 2011 4:33 am | by Bio-Medicine.Org | News | Comments

BOSTON, Sept. 19, 2011 /- The 15th Annual Scientific Meeting of the Heart Failure Society of America (HFSA) will feature a session entitled "Late Breaking Trials," which will highlight recent studies relating to heart failure. Dr. D.J. van Veldhuisen, from The UMC Groningen, The...

Haemonetics handed a loss in pair of patent suits

September 16, 2011 10:34 am | by Mass High Tech: The Journal of New England Technology | News | Comments

Blood management company Haemonetics Corp. has lost a pair of lawsuits it had brought against Illinois firm Fenwal Inc. over red blood cell separation technology.

Mindray Introduces DP-50 Portable Ultrasound System in the U.S.

September 16, 2011 6:34 am | by Bio-Medicine.Org | News | Comments

MAHWAH, New Jersey, Sept. 16, 2011 /PRNewswire-Asia-FirstCall/ -- Mindray Medical International Limited (NYSE: MR ), a leading developer, manufacturer and marketer of medical devices worldwide, today announced the introduction of the company's new DP-50 ultrasound system in the United...

Advertisement

Pathfinder Cell Therapy, Inc. Announces New Stock Ticker Symbol

September 16, 2011 6:34 am | by Bio-Medicine.Org | News | Comments

CAMBRIDGE, Mass., Sept. 16, 2011 /- Pathfinder Cell Therapy, Inc. ("Pathfinder")(OTCQB: PFND), a biotechnology company focused on the treatment of diseases characterized by organ-specific cell damage, today announced that effective at the start of trading today, the ticker symbol for its...

Drug-Driving: Draw the Line Now

September 16, 2011 4:33 am | by Bio-Medicine.Org | News | Comments

LONDON, September 16, 2011 /- Concateno Welcomes the Campaign to Make Lillian's Law a Reality On the 7 th July, John Page was sentenced to eight months in prison for dangerous driving that led to the death of 14-year-old Lillian Groves. Page's vehicle hit Lillian while she was...

Aperion Biologics Invited to Present at the UBS Global Life Sciences Conference

September 16, 2011 4:33 am | by Bio-Medicine.Org | News | Comments

SAN ANTONIO, Sept. 16, 2011 /- Aperion Biologics, Inc. announced today that the company will be presenting at the 2011 UBS Global Life Sciences Conference at the Grand Hyatt New York on Wednesday, September 21, 2011 at 3:00 PM (EDT). Daniel Lee, Chief Executive Officer, is scheduled to...

Targeting Cholesterol May Help Slow Glioblastoma

September 15, 2011 9:33 am | by AACR | News | Comments

Tweet •    These lethal brain cancers depend on cholesterol for growth.•    Laboratory findings identified a tumor survival pathway.•    Glioblastoma is one of the most untreatable cancers. PHILADELPHIA — Glioblastoma is...

Alexza Pharmaceuticals to Present at the Sixth Annual JMP Securities Healthcare Conference

September 15, 2011 7:33 am | by Bio-Medicine.Org | News | Comments

MOUNTAIN VIEW, Calif., Sept. 15, 2011 /- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA ) announced today that the company will participate in the Sixth Annual JMP Securities Healthcare Conference, being held in New York, New York, September 27 - 28, 2011.  The Alexza corporate...

Advertisement

Lupin Announces Launch of Generic KEPPRA XR® Tablets

September 14, 2011 10:34 am | by Bio-Medicine.Org | News | Comments

BALTIMORE, Sept. 14, 2011 /- Lupin Pharmaceuticals, Inc. (LPI) announced today that the U.S. Food and Drug Administration (FDA) has granted final approval for the Company's Abbreviated New Drug Application (ANDA) to market a generic version of UCB's KEPPRA XR tablets.  Commercial...

Innovative Companies to Present at AdvaMed 2011: The Medtech Conference in Washington, D.C.

September 14, 2011 10:33 am | by Bio-Medicine.Org | News | Comments

WASHINGTON, Sept. 14, 2011 /PRNewswire-USNewswire/ -- Medical technology manufacturers from across the United States and around the globe will present their technologies at AdvaMed 2011: The Medtech Conference.  More than 60 innovative device and diagnostic companies and academic...

Delcath Systems, Inc. Hosts Symposium on Chemosaturation at CIRSE Annual Meeting

September 14, 2011 4:33 am | by Bio-Medicine.Org | News | Comments

NEW YORK, Sept. 14, 2011 /- Delcath Systems, Inc. (NASDAQ: DCTH ) today announced that the Company sponsored an industry symposium at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) in Munich, Germany—the largest international forum for minimally...

American Pharmacists Association Partners with HHS, CDC and CMS in the Million Hearts Initiative

September 13, 2011 12:33 pm | by Bio-Medicine.Org | News | Comments

WASHINGTON, Sept. 13, 2011 /PRNewswire-USNewswire/ -- The American Pharmacists Association (APhA) announced it has joined the newly launched Million Hearts Initiative, a coordinated approach to preventing cardiovascular disease and stroke in the U.S. Co-led by the U.S. Department of...

Emergency Nurses Association Announces Corporate Sponsors for Annual Conference

September 13, 2011 9:34 am | by Bio-Medicine.Org | News | Comments

DES PLAINES, Ill., Sept. 13, 2011 /PRNewswire-USNewswire/ -- The Emergency Nurses Association (ENA) today announced the corporate sponsors for the ENA Annual Conference to be held in Tampa on September 20-24, 2011. This year's Strategic Sponsors are Stryker and Vidacare; the Strategic...

Polymedco, Inc., and Cardinal Health Sign Agreement for Distribution of Oncologic Diagnostic Test Kits to Acute Care Market

September 13, 2011 6:33 am | by Bio-Medicine.Org | News | Comments

CORTLANDT MANOR, N.Y., Sept. 13, 2011 /- Polymedco, Inc. is pleased to announce its exclusive agreement with Cardinal Health, Inc., for distribution of its market leading automated FIT product, a fecal occult blood analyzer that can help increase patient compliance rates and aid in the...

LX4211 for Diabetes Shown to Reduce Fasting and Post-Prandial Blood Sugar in Healthy Subjects

September 13, 2011 4:33 am | by Bio-Medicine.Org | News | Comments

THE WOODLANDS, Texas, Sept. 13, 2011 /- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX ), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, reported positive data from a recently completed clinical trial and mechanistic study of LX4211, a dual...

External Defibrillator Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2017

September 13, 2011 1:33 am | by Bio-Medicine.Org | News | Comments

NEW YORK, Sept. 13, 2011 /- Reportlinker.com announces that a new market research report is available in its catalogue: External Defibrillator Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2017 ...

Spaulding Clinical Announces New Strategic Partnership With Frontage Laboratories, Inc.

September 12, 2011 8:34 am | by Bio-Medicine.Org | News | Comments

WEST BEND, Wis., Sept. 12, 2011 /- Frontage Laboratories, Inc., a global full-service Clinical Research Organization with facilities in the US and China, and Spaulding Clinical Research, LLC, a US-based, leading-edge Clinical Pharmacology Unit, ECG Core Lab, and Medical Device...

Out of the Darkness

September 12, 2011 8:34 am | by Bio-Medicine.Org | News | Comments

SAN DIEGO, September 12, 2011 /- - Digital issue looks inside the minds, lives & hearts of responders to 9-11-01 The Journal of Emergency Medical Services ( JEMS ) today announces the publication of a special 150-page four-volume digital issue featuring first-person accounts...

First Client Installation of CyttaConnectâ„¢ Medical Monitoring System

September 12, 2011 8:34 am | by Bio-Medicine.Org | News | Comments

LOS ANGELES, Sept. 12, 2011 /- Cytta Corp (OTCQB: CYCA) is pleased to announce that we have now successfully completed the first client installation and deployment of our remote medical monitoring system.  This installation enables the Company to commence a full scale roll out of its...

Analyses Find Type 2 Diabetes Patients Treated with BYDUREONâ„¢ Experienced Reduction in Cardiovascular Risk Factors: Results Presented at EASD 2011

September 12, 2011 3:33 am | by Bio-Medicine.Org | News | Comments

LISBON, Portugal, Sept. 12, 2011 /- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN ), Eli Lilly and Company (NYSE: LLY ) and Alkermes, Inc. (Nasdaq: ALKS ) today announced new analyses from the DURATION-3 and -4 trials demonstrating patients treated with the investigational medication...

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading